J. Infect. Dis., 2015
Influence of Statins on Influenza Vaccine Response in Elderly Individuals.
Black, S; Nicolay, U; Del Giudice, G; Rappuoli, R
Influenza vaccination strategies have targeted elderly individuals because they are at high risk of disease complications and mortality. Statins are a class of drugs used to treat hypercholesterolemia and are frequently used in the elderly population to reduce the risk of cardiovascular disease. However, statins are also known to have immunomodulatory effects that could impact influenza vaccine response. In a post hoc analysis, we performed a cross-sectional observational study nested within a comparative immunogenicity clinical trial of adjuvanted versus unadjuvanted influenza vaccine in elderly persons to evaluate the influence of statin therapy on the immune response to vaccination. Overall, data on >5000 trial participants were available for analysis. Comparison of hemagglutination-inhibiting geometric mean titers to influenza A(H1N1), A(H3N2), and B strains revealed that titers were 38% (95% confidence interval [CI], 27%-50%), 67% (95% CI, 54%-80%), and 38% (95% CI, 28%-29%) lower, respectively, in subjects receiving chronic statin therapy, compared with those not receiving chronic statin therapy. This apparent immunosuppressive effect of statins on the vaccine immune response was most dramatic in individuals receiving synthetic statins. These effects were seen in both the adjuvanted and unadjuvanted vaccine groups in the clinical trial. These results, if confirmed, could have implications both for future clinical trials design, as well as for vaccine use recommendations for elderly individuals.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
PMID: 26516142
URL - http://www.ncbi.nlm.nih.gov/pubmed/26516142?dopt=Citation
cheers Rob
Sent from a device with a ridiculously small keyboard , apologies for any tyops.
hVIVO is the new name of Retroscreen Virology! (from 15 April 2015). hVIVO is a rapidly growing UK life sciences company pioneering a technology platform which uses human challenge models of disease involving healthy volunteers to study new drugs and investigate disease in a safe, controlled, clinical environment. Our belief is that the best way to understand human disease is by studying it in humans, not laboratory models.
No comments:
Post a Comment